NEUROMYELITIS OPTICA SPECTRUM DISEASE (NMOSD)
Clinical trials for NEUROMYELITIS OPTICA SPECTRUM DISEASE (NMOSD) explained in plain language.
Never miss a new study
Get alerted when new NEUROMYELITIS OPTICA SPECTRUM DISEASE (NMOSD) trials appear
Sign up with your email to follow new studies for NEUROMYELITIS OPTICA SPECTRUM DISEASE (NMOSD), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug aims to tame rare nerve disease
Disease control Not yet recruitingThis trial tests a drug called ripertamab in people with neuromyelitis optica spectrum disorder (NMOSD), a rare condition where the immune system attacks the optic nerves and spinal cord. Participants receive the drug by IV infusion four times over 73 weeks and are monitored for …
Matched conditions: NEUROMYELITIS OPTICA SPECTRUM DISEASE (NMOSD)
Phase: PHASE1, PHASE2 • Sponsor: Zhongming Qiu • Aim: Disease control
Last updated Jul 08, 2026 00:00 UTC
-
Experimental CAR-T therapy targets devastating nerve disease
Disease control Not yet recruitingThis early-phase trial tests a new treatment called KSVCBD, a type of CAR-T cell therapy, for people with a severe autoimmune disease called neuromyelitis optica spectrum disorder (NMOSD) that has not responded to standard treatments. The study will include 18 adults who test pos…
Matched conditions: NEUROMYELITIS OPTICA SPECTRUM DISEASE (NMOSD)
Phase: EARLY_PHASE1 • Sponsor: Chinese PLA General Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:34 UTC